Memigmin

Memantine Hydrochloride, the active ingredient in Memigmin, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adults.

GNH USA supplies Memigmin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memigmin is a NMDA‑receptor antagonist used in the management of Alzheimer’s disease and related cognitive disorders. - Moderate to severe Alzheimer’s disease: improves cognition, memory and daily functional abilities. - Behavioral disturbances in Alzheimer’s disease: may reduce agitation, aggression and psychotic symptoms. - Dementia of Alzheimer’s type: supports overall cognitive performance and slows functional decline.

Common Side Effects: - Dizziness: feeling light‑headed or unsteady. - Headache: mild to moderate pain in the head. - Constipation: reduced bowel movements. - Confusion: transient disorientation or difficulty concentrating. - Fatigue: unusual tiredness or lack of energy. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Seizures: sudden uncontrolled electrical activity in the brain. - Severe rash or skin reactions: including Stevens‑Johnson syndrome. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Suicidal thoughts: emergence of depressive ideation. - Cardiac arrhythmia: irregular heart rhythm. - Psychosis: new or worsening hallucinations or delusions.

Memigmin should be used with caution in specific clinical situations. - Renal impairment: assess kidney function and consider dose adjustment. - Hepatic impairment: monitor liver enzymes regularly. - History of seizures: evaluate risk and monitor closely. - Concurrent use of other NMDA antagonists: avoid additive neurotoxicity. - Pregnancy: safety not established; use only if benefit outweighs risk. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Memigmin may interact with several medicines; monitoring is advised. Major Interactions (Avoid): - Amantadine: combined NMDA antagonism can increase neurotoxicity. - Other NMDA antagonists (e.g., ketamine): risk of additive CNS effects. - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may lower memantine plasma concentrations. Moderate Interactions (Monitor Closely): - Anticholinergic agents: may diminish therapeutic benefit. - Diuretics: can enhance risk of hypotension. - Alcohol: may potentiate central nervous system depression.